Moderna stock edges lower as insider sales follow recent trial optimism
Published on 09/16/2026 at 18:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna Inc. stock (ISIN US60770K1034) closed at USD 143.77 on the Nasdaq on September 15, 2026, roughly 2.0% below the previous session’s close of USD 146.69, highlighting renewed volatility around the vaccine maker’s shares as insider transactions draw attention in mid-September 2026 per Nasdaq data cited in recent market summaries.
Insider selling adds to September pressure
According to MarketBeat on September 15, 2026, Moderna shares slipped to an intraday low of USD 141.16 and last traded at USD 143.77 on the Nasdaq, compared with a prior close of USD 146.69, reflecting a 2.0% decline for the day.
The same overview notes that Moderna’s chief financial officer Jamey Mock sold 34,836 shares of company stock, with proceeds of about USD 4.7 million, reducing his direct ownership by around 37%, an insider move that investors are watching closely as it coincides with the latest pullback in the share price.MarketBeat
Analyst consensus and valuation context
According to MarketBeat, analyst views on Moderna remain mixed, with seven Buy, twelve Hold and five Sell recommendations, yielding an overall consensus rating of Hold and an average price target of USD 76.72, noticeably below the USD 143.77 closing level on September 15, 2026.
At that closing price, the shares traded almost 87.3% above the average analyst target of USD 76.72, underscoring how market optimism about Moderna’s mRNA pipeline and recent trial progress is currently at odds with more cautious valuation models from Wall Street.MarketBeat
Earnings trends highlight widening losses
Earnings estimates and recent results add another layer to the debate about Moderna’s valuation. Data compiled by Yahoo Finance show that Moderna reported earnings per share of USD -1.97 in Q2 fiscal 2026, compared with a consensus estimate of USD -2.06, implying a positive surprise of USD 0.09 per share or about 4.3%.
The same earnings history indicates that Moderna’s EPS in Q1 fiscal 2026 came in at USD -3.40 versus an estimate of USD -3.88, a beat of USD 0.48 per share and a surprise of roughly 12.4%, while Q4 fiscal 2025 EPS reached USD -2.11 against an expected USD -2.60, another beat of USD 0.49 per share and an 18.9% surprise.Yahoo Finance
Despite these recurring beats versus consensus, the figures still point to sizeable losses, with Q2 fiscal 2026 revenue of around USD 145 million and net earnings of about USD -782 million translating into a profit margin near -539.3%, according to the same set of data.Yahoo Finance
Forward-looking estimates and upcoming earnings date
Looking ahead, the consensus compiled by Yahoo Finance as of mid-September 2026 implies an expected EPS of USD -1.29 for the quarter ending in September 2026 and USD -1.74 for the December 2026 quarter, while estimates for the full year 2026 and 2027 stand at USD -8.38 and USD -4.79 respectively.
Additional calendar data from Zacks on September 16, 2026 indicate that Moderna’s next earnings release is expected on November 5, 2026 for the quarter ending in September 2026, with the consensus pointing to EPS of USD -1.36, a projected year-over-year decline of roughly 166.7% compared with USD -0.51 in the same quarter a year earlier.
Stock price level and trading range
Per recent Nasdaq-related data cited in regional market overviews, Moderna stock’s closing price of USD 143.77 on September 15, 2026 on the Nasdaq came after the shares traded between USD 141.16 and about USD 147 during that session, while the prior close of USD 146.69 marked a stronger level that had been reached earlier in mid-September.
Separate quote data compiled by a financial portal show a 52-week price range for Moderna of USD 62.55 to USD 170.47 as of a recent update, meaning that the USD 143.77 close on September 15, 2026 left the stock around 130% above the 52-week low and roughly 15.6% below the 52-week high, a positioning that underlines the strong recovery from earlier lows but also a notable gap to the most recent peak.
Key data on Moderna stock
- Company: Moderna Inc.
- ISIN: US60770K1034
- Ticker: MRNA
- Trading venue: Nasdaq
- Price (as of September 15, 2026): 143.77 USD
- Market capitalization: 58,600,000,000 USD (as of September 14, 2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: S&P 500
- Next earnings date: November 5, 2026
